Illustrative image – not actual.
Metropolis Healthcare will expand into tier-II, III, and IV towns across Uttar Pradesh, Madhya Pradesh, Andhra Pradesh, Telangana, and Assam. This strategic move aims to tap into the growth potential of underserved markets with limited high-quality diagnostic services.
The company is focusing on enhancing offerings in therapeutic areas such as neurology and oncology. To stay ahead, it is investing in genomics and molecular diagnostics. Metropolis is also directing investments into new areas to fuel growth and innovation, such as in therapeutic areas such as transplants, neurology, nephrology, gastroenterology, and oncology.
Metropolis aims to boost its collection centre networks and enhance service standards, particularly in Tier-II and III markets. The company would strengthen its B2B presence internationally, leveraging its Global Reference Laboratory as a specialty testing hub. Metropolis is also eyeing local B2C brands in certain markets.
For organic growth, it plans to lead in new test advancements and strengthen relationships with specialty doctors. It looks to acquire firms with capabilities to enhance its technical testing and distribution network. It is focusing on strategic acquisitions nationwide to strengthen market position, and continues to uphold a presence in established markets in the south and west, while targeting regions in northeast and central India to ensure comprehensive nationwide coverage.
